An2 Therapeutics (ANTX)CEO bought ~$11K

~$11K

Approx. value · 10K sh @ $1.07

256K

Holds after · shares reported

Traded

Jun 2, 2025

Filed

Jun 3, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 28, 2025Insider · 2 peopleInsiders: 1 purchase (~$10K), 3 sales (~$2.7M)
2. May 30, 2025Insider · 1 personInsiders: 2 sales (~$436K)
3. Jun 2, 2025 · this disclosureInsiderCEO purchased ~$11K of ANTX shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for An2 Therapeutics

For An2 Therapeutics, OQRO holds 10 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ANTX page.

Other recent filings by Eric Easom, Chief Executive Officer

• SEC Form 4 at An2 Therapeutics (ANTX)Nov 19, 2024

The full history of Eric Easom, Chief Executive Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at An2 Therapeutics

• SEC Form 4Sep 11, 2026
• SEC Form 4Sep 11, 2026
• SEC Form 4Sep 8, 2026
• SEC Form 4Sep 8, 2026
• SEC Form 4Sep 8, 2026
• SEC Form 4Sep 8, 2026

Everything OQRO holds on this company is on its ANTX page.